Skip to content
5 min read The Long View the-long-view

The Long View: Partner, Rival Or Dinner Guest

China's share of big pharma licensing deals went from 5% to 39% in five years. The factory of the future will have no humans on the floor. A dinner at the White House is hopefully discussing both.

A large gorilla resting on a wooden platform, chin resting on its hand, looking directly at the camera.
Unbothered. Unmatched. Uninvited. Photo by Valentin Jorel on Unsplash

What does a high-profile dinner between political juggernauts look like? Elaborate ceremonies, glitz and glamour, a fancy spread and at least the impression of progress toward aligned geopolitical goals. Add a sprinkle of tech moguls to the broth and the conversation could get spicy. The Long View previously spoke about “doomsayers” and the threat of AI to humanity — so at least the dinner guests have something to talk about. The Long View hates awkward silences too.

This week, US president Donald Trump hosted his Chinese counterpart Xi Jinping at a state dinner. Miles away in London, the biopharma industry was having its own version of a tense dinner with conversations centred on China's growing role in global drug development.

Partner Or Rival

China’s share of big pharma licensing deals valued at $50m or more has been transformed, from just 5% in 2021 to 39% last year, according to a July J.P. Morgan biopharma report. The trend has continued in the first six months of this year, with China-origin assets reaching 42% of deals and representing 68% of the upfront dollars across these transactions.